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The Z mutation (E342K) of 1-antitrypsin (1-AT), carried
by 4% of Northern Europeans, predisposes to early onset of
emphysema due to decreased functional 1-AT in the lung and
to liver cirrhosis due to accumulation of polymers in hepato-
cytes. However, it remains unclear why the Z mutation causes
intracellular polymerizationof nascentZ1-ATandwhy15%of
the expressedZ1-AT is secreted into circulation as functional,
but polymerogenic, monomers. Here, we solve the crystal struc-
ture of the Z-monomer and have engineered replacements to
assess the conformational role of residueGlu-342 in1-AT.The
results reveal that Z 1-AT has a labile strand 5 of the central
-sheet A (s5A)with a consequent equilibriumbetween a native
inhibitory conformation, as in its crystal structure here, and an
aberrant conformation with s5A only partially incorporated
into the central -sheet. This aberrant conformation, induced
by the loss of interactions from the Glu-342 side chain, explains
why Z 1-AT is prone to polymerization and readily binds to a
6-mer peptide, and it supports that annealing of s5A into the
central -sheet is a crucial step in the serpins’ metastable con-
formational formation. The demonstration that the aberrant
conformation can be rectified through stabilization of the labile
s5Abybinding of a smallmolecule opens a potential therapeutic
approach for Z 1-AT deficiency.
Serpins (1–3) are folded into ametastable conformationwith
a surface-exposed reactive center loop (Fig. 1a). Once the reac-
tive loop is recognized and cleaved by the target protease, a
dramatic conformational change occurs, with the incorpora-
tion of the reactive loop into themiddle of the central-sheet A
and a translocation and inactivation of the covalently linked
protease (4–6). This unique change from a metastable to
hyperstable conformation (Fig. 1b) is accompanied by a large
free energy change, which is utilized for protease inhibition.
However, the native metastable conformation is susceptible
to point mutations that cause serpin misfolding and polymeri-
zation and subsequent retention of stable serpin polymers
within the endoplasmic reticulumof cells (7, 8). TheZmutation
(E342K) of 1-antitrypsin (1-AT),4 carried by 4% of Northern
Europeans, predisposes to the early onset of emphysema due to
decreased functional 1-AT in the lung and to liver cirrhosis
due to accumulation of 1-AT polymers in the endoplasmic
reticulum of hepatocytes (9–12). Glu-342 is located at the top
of strand 5 of central-sheet A (s5A) in the P17 position (active
site residue termed P1) at the base of the reactive center loop
and forms a highly conserved salt bridge to Lys-290 and a
hydrogen bond to Thr-203 (Fig. 1a). This together with main
chain packing effectively forces the reactive loop to take a turn
with residue 342 acting as a hinge (13).
The mechanism by which the E342K mutation causes poly-
merization of Z 1-AT is not fully understood, and various
models of serpin polymerization have been proposed (12,
14–18). The “classic” loop-sheet model proposed that serpin
polymers could form by the intermolecular linkage of the reac-
tive loop of onemolecule with the-sheet A of another (12, 14).
Similarly a -hairpin model was proposed based on the crystal
structure of an antithrombin dimer (Fig. 1d) with a larger
domain swap, including the reactive loop and strand 5 of the
central -sheet A (s5A) (16), but subsequent immunological
evidence challenged this as the linkage that occurs in vivo (19,
20). A later serpin polymerizationmodel, derived from the crys-
tal structure of an 1-AT trimer (17) (Fig. 1e), proposes that
polymerization in vivo occurs through a C-terminal domain
swapmechanism involving strands 4 and 5 of-sheet B (s4/5B).
However, these models do not satisfyingly explain how exactly
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the mutation of Glu-342 affects the folding pathway of 1-AT
leading to polymerization, and the folding pathway of 1-AT
proposed from the trimer structure (17) contradicts a subse-
quent model derived from biochemical studies (21, 22). Also
unexplained is the finding that15% of the expressed Z1-AT
is secreted into the plasma as an active, but unstable, monomer.
This circulating Z 1-AT seems to adopt an aberrant confor-
mation with a high basal fluorescence signal (23), which pref-
erentially binds to a 6-mer peptide (FLEAIG) derived from its
reactive center loop (23).
Here, we have assessed the role of residue 342 in 1-AT and
solved the crystal structure of theZ1-ATmonomer.Our find-
ings reveal how themutation of Glu-342 would lead to an aber-
rant conformation of Z 1-AT and explain how the Zmutation
will disrupt a key step in the folding pathway of 1-AT leading
to its pathological polymerization.
Results
Role of Residue 342 in 1-AT Folding—The Z mutation
(E342K) will not only result in the direct loss of the stabilizing
interactions ofGlu-342 butwill also perturb the nearby packing
due to the positive charge of the lysine side chain. However,
there is no consensus as to which is the main contributing fac-
tor (24–27). To dissect this, we systematicallymutatedGlu-342
to the 19 other common amino acids and expressed these vari-
ants in a bacterial expression system that eliminates the effects
of glycosylation and chaperone on folding as seen in mamma-
lian cells. All the variants mentioned in this paper are based on
the well documented Pittsburgh variant of 1-AT with an Arg
at the P1 position (28) for convenient assessment of conforma-
tional change effects toward protease inhibition, and 1-AT-
Pittsburgh is termed wild type here. We then compared the
levels of overall expression of 1-AT and also of the soluble
fractions of the expressed protein by SDS-PAGE. The overall
expression level will represent how well the gene is transcribed
and translated in Escherichia coli, whereas the soluble fraction
measures how efficiently the recombinant protein folds into a
normal conformation.
As expected, we found that the overall expression level of all
these 1-AT variants were similar, indicating that the muta-
tions have little effect on 1-AT gene transcription and trans-
lation. Therefore, the soluble fraction of the expressed 1-AT
for each variant will represent the variant’s folding efficiency.
The soluble fractions for all the variants were analyzed by SDS-
PAGE and Western blotting (Fig. 2a). This revealed that all 19
mutations caused a significant reduction (70–90%) in the
expression of soluble 1-AT as compared with the wild type.
This is consistent with the notion that Glu-342 is critical for the
folding of 1-AT. Among the mutants, E342D mutant has a
lesser reduction (70%), likely due to partial preservation of
stabilizing interactions by the chemically similar Asp side
chain. Notably, soluble fractions from mutants where Glu-342
is mutated to residues with smaller side chains such as Ala and
Gly are decreased to10% ofwild type1-AT, andArg and Lys
mutations seem to have an even greater decrease with the sol-
uble fractions being only5% of the wild type.
As this aggravating effect of Arg and Lys likely arises from
their positively charged side chains, we performed refolding
experiments to test the effect on folding of charges at position
342. The denatured 1-AT E342H mutant was diluted into
refolding buffer of different pH values, and the inhibitory activ-
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FIGURE 1. Conformations of 1-AT. a, metastable conformation of wild type 1-AT. Glu-342, located at the base of the reactive center loop (yellow), forms
hydrogen bonds with Thr-203 and Lys-290. The so-called shutter region, which opens during reactive loop insertion, is circled by dashed lines. Atoms C of
residue 229 and339 for an engineereddisulfidebondare shownas spheres. Trp-194below thehinge region and surrounding residuesAsp-341 and Lys-191 are
shown as sticks. Once the reactive loop (yellow) is cleaved by protease, it is inserted into the central -sheet (red) as a middle strand forming a hyperstable
conformation (b). The peptide which encodes sequence from the serpin-reactive loop could also insert into the central -sheet as amiddle strand converting
serpin into ahyper-stablebinary complex conformation (c). Polymersmay form though s4/5Adomain swap linkagederived fromantithrombindimer structure
(d) and the C-terminal s4/5B (cyan) linkages derived from crystal structure of 1-AT trimer (e).
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ity of the folded 1-AT was assessed by SDS-PAGE. As shown
in Fig. 2b, the correctly folded wild type 1-AT readily formed
a stable complex with protease, with similar amounts being
formed over a pH range of 5–9. This shows that refolding of
wild type 1-AT is not affected by changes of pH.However, pH
changes have a significant effect on folding of E342H with a
much lower yield at pH 5 and a higher yield at pH 9 (Fig. 2b,
right gel). The increased amount of cleaved 1-AT E342H is
proportional to the amount of complexes formed as indicated
by densitometry analysis of the bands, which is consistent with
the increased SI of Glu-342 variants and substrate behavior of
misfolded proteins (29). As the histidine side chain is proto-
nated around pH 5 and therefore positively charged, and is
largely uncharged when the pH is above 8, this indicates that a
positive charge at position 342 has an aggravating effect on the
folding of 1-AT. Overall, the finding here indicates that the
loss of the Glu-342 side chain, as seen with the E342A mutant,
results in a significant (10-fold) decrease in folded 1-AT,
although a positive charge at position 342 aggravates the fold-
ing process further.
Role of Residue 342 in 1-AT Activities—Subsequently, we
attempted to purify and characterize the recombinant Z1-AT
(E342K) variant from the soluble fraction ofE. coli,butwe failed
to get sufficient protein for further study. So we took an alter-
native approach by purifying a E342C mutant and then con-
verting Cys-342 to a lysine-like residue in vitro by chemical
modification (Fig. 3). The modified E342C variant, termed
E342C-mod, was verified by mass spectrometry analysis. We
then tested the inhibitory activities of the E342C, E342C-mod,
and wild type 1-AT variants against thrombin and activated
factor X (FXa). As shown in Table 1, all themutants have nearly
doubled stoichiometry of inhibition (SI) toward thrombin and
FXa when compared with the wild type. Notably, the E342C
mutant has an almost identical association rate (ka) and stoi-
chiometric inhibition (SI) to those of E342C-mod in inhibiting
thrombin,with the twomutants inhibiting thrombinmore than
2.5-fold faster than the wild type protein. E342C mutant has a
similar SI (3.0) as that of E342C-mod toward FXa. Therefore,
the Z-like 1-ATmutant is still a good protease inhibitor but is
less efficient as it requires about 2–3 molecules of inhibitor,
instead of 1 with wild type 1-AT, to inhibit one protease mol-
ecule. This is consistent with previous observations that Z
1-ATderived fromhuman plasma or recombinant Z1-AT is
largely active in inhibiting protease, althoughwith increased SIs
(30–32). Also, these data indicate that, once the 1-ATmutant
is folded, the positive charge at residue 342 has little effect on
the inhibitory activity of 1-AT because both E342C and
E342C-mod behave similarly toward protease (Table 1).
Role of Residue 342 in 1-AT Conformations—To test the
effect of these mutations at position 342 on 1-AT conforma-
tions, we performed a peptide annealing experiment in which
Glu-342 variants were mixed with the 6-mer peptide FLEAIG,
derived from P7 to P2 sequence of 1-AT reactive loop, and
assessed for binary complex formation. It has been shown that
peptides encoding the reactive center loop sequence could
insert into the central-sheetA as strand 4 (Fig. 1c) and convert
a serpin into a hyperstable conformation (33, 34), which is
resistant to denaturation in 7 M urea. As shown in Fig. 3a, plas-
ma-derived Z 1-AT forms the 1-AT peptide hyperstable
binary complex much faster than plasma-derived normal M
1-AT, which is consistent with previous observations (23, 35).
As expected, E342C-mod readily forms a urea stable binary
complex as seen with plasma-derived Z 1-AT. However,
E342A and E342C mutants similarly form a binary complex
with the 6-mer peptide much faster than wild type 1-AT (Fig.
3a). This suggests that all the Glu-342 mutants, regardless of
the side chain of residue 342, can adopt an aberrant conforma-
tion, similar to that of plasma Z 1-AT, which binds the 6-mer
peptide preferentially. Therefore, we conclude that the aber-
rant conformation of 1-AT arises from the loss of the stabiliz-
ing interactions of Glu-342 in wild type 1-AT, rather than
from the positive charge of Lys in the Z variant.
FIGURE 2. Effect of residue 342 on folding of 1-AT. a, 20 1-AT variants with different residues at position 342 were expressed in E. coli, and the soluble
fractions of the expressed1-ATwere analyzedby SDS-PAGE andWesternblotting. The insetgel is shownas an example. The relative expression levels derived
from densitometry analysis of four independent experiments were plotted with the wild type as mean  S.D. The expression levels of all the mutants are
significantly different from that ofwild type1-ATwithp value 0.05 as determinedby Student’s t tests.b,pHeffects on the refoldingofWTandE342H1-AT.
Denatured1-ATwas quickly diluted into refolding buffer of different pH values. The refolded1-AT samples were thenmixedwith excess thrombin (IIa) and
assessed for 1-ATthrombin complex formation. The samples from wild type 1-AT refolding were analyzed by SDS-PAGE and Coomassie Blue staining (left
gel), and samples for E342Hwere analyzed byWestern blot (right gel) using anti-1-AT antibody. The comparative result of densitometry analysis for complex
or cleaved bands was shown in the gel, and the quantity of complex or cleaved 1-AT formation at pH 5 was set to 1.
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Stabilization of s5A by a Disulfide Bridge—Because Glu-342
is located at the top of s5A and its key interaction is to anchor
s5A to s6A, we engineered an alternative stabilizing interaction
through a disulfide bond linking s5A and s6A (Fig. 1a) as
described previously (16). This disulfide bond was used to
probe intermolecular linkage between s5A and s6A (16), and
here we tested its effect on the aberrant conformational change
of Z 1-AT. These mutations (S292C and T339C) were intro-
duced onto a E342A 1-AT background. Both the oxidized and
reduced forms of this mutant (1-AT-S292C-T339C-E342A,
termed 1-AT-SS-E342A) were prepared and assessed in the
peptide annealing experiment. As expected, under reducing
conditions this mutant preferentially binds to the 6-mer pep-
tide, as does the unmodified E342A mutant (Fig. 3a). The oxi-
dized form, however, where s5A is fixed by a disulfide bond,
behaves like wild type 1-AT, with slower insertion of the
6-mer peptide.
Notably, the oxidized form has a thermal stability similar to
that of thewild type, being largely stable at 50 °C, but it becomes
less stable under reducing conditions and is prone to form
aggregates and polymers at 50 °C as does the E342A variant
(Fig. 3c). This is in line with previous findings that plasma-
derived Z1-AT is less stable than normalM1-AT and forms
FIGURE 3. 1-AT conformation probed by peptide annealing experiment (a), chemical modification (b), thermal stability assay (c), and fluorescent
measurements (d and e). a, 1-AT variants (0.5 mg/ml) were incubated with 100-fold excess 6-mer (FLEAIG) peptide at 37 °C for different time intervals and
then analyzed by a native gel containing 7 M urea. The 1-ATpeptide binary complex (BC, arrows) is hyperstable and resistant to urea denaturation and
migrates faster than theunfolded1-AT. PlasmaZ1-AT, recombinant E342A, E342C, andE342C-mod1-ATvariants formabinary complex faster thanplasma
M1-AT and recombinantwild type (Wt). The oxidized formof1-ATmutant (S292C, T339C, and E342A, termed1-AT-SS-E342A), where s5A is fixed to s6A by
a disulfide bridge (Oxi), binds to 6-mer peptide slowly; however, its reduced form (red) readily binds to 6-mer peptide similar to other Glu-342 mutants. b,
aminoethyl-8 reagent specifically reacts with thiol group and converts the cysteine side chain to a lysine-like structure. c, 1-AT variants were incubated at
various temperatures in 10 mM Tris-HCl, pH 7.4, 0.1 M NaCl, and 0.5 M urea for 30 min and then analyzed by native gel electrophoresis. E342A mutant (E342A)
has reduced thermal stability as compared with wild type 1-AT (Wt). The oxidized 1-AT mutant (Oxi) has similar thermal stability as that of the WT, but it
becomes less stable once the disulfide is reduced (red). d and e, fluorescence emission spectra of 1-AT variants weremeasured at excitation wavelength 290
nm. The spectra of plasmaM 1-AT is shown as a black solid line and Z 1-AT as a dashed line (d). The reduced form of themutant 1-AT-SS-E342A is shown as
a black dashed line, and the oxidized form as a black solid line. The spectra of the D341A variant and the wild type are shown in blue and red solid lines,
respectively (e).
TABLE 1
Inhibitionparameters (KaandSI) for1-ATvariants towardthrombinand
activated factor X (FXa)
All the variants are based on 1-AT Pittsburgh backbone with (M358R and C232S).
Each value was the average of three independentmeasurements with standard error
shown.
Thrombin FXa
Ka SI KaSI Ka SI KaSI
M1 s1 M1 s1 M1 s1 M1 s1
Wild type 1.1 0.1e5 1.6 0.1 1.1e5 3.6 0.1e4 1.3 0.1 4.7e4
E342C 0.93 0.1e5 3.0 0.1 2.8e5 2.3 0.1e4 3.0 0.1 6.9e4
E342C-mod 0.88 0.1e5 3.4 0.2 3.0e5 1.2 0.1e4 3.4 0.1 4.1e4
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polymer after incubation at 37 °C or slightly elevated tempera-
ture (30).
Furthermore, fluorescence spectroscopic measurements
showed that E342Amutant has a higher basal fluorescence sig-
nal than thewild type,which resembles those of plasma-derived
normalM1-AT andZ1-AT (Fig. 3, d and e). To test whether
formation of the disulfide bond in mutant 1-AT-SS-E342A
induces any conformational change, the spectra of reduced or
oxidized forms of this mutant were measured (Fig. 3e). The
spectrum of the oxidized form resembles that of wild type
1-AT; however, once the disulfide is reduced, there is a sub-
stantial increase in the fluorescence intensity at 340 nm (Fig.
3e). These spectra are consistent with previous suggestions that
Trp-194 (Figs. 1a and 3d), which is buried in the hinge region
and forms hydrophobic interactionswithMet-242 andTyr-244
of s2/3B in the wild type 1-AT, becomes more solvent acces-
sible in the Z conformation (31, 36). Therefore, we conclude
that Z 1-AT has an unstable central -sheet A, which allows
preferential insertion of the 6-mer peptide, and the top half of
s5A is labile with Trp-194 readily exposed.
Probing the Aberrant Conformation through mPEG Modifi-
cation—It was proposed that Z 1-AT might have a partially
open -sheet A with the reactive loop partially inserted (Fig.
4b), similar to the -conformation of antichymotrypsin (37).
This would allow ready insertion of a short peptide, such as
FLEAIG, into the lower half of -sheet A, but not the longer
peptide encoding P14-P3 of the reactive center loop (23). To
test this hypothesis, we prepared two mutants with the P14
(Thr-345) residue replaced by Cys (Fig. 4a), on the backbone of
both wild type and E342A 1-AT. Similarly, mutants with res-
idues Ile-340, Leu-338, and Ala-336 around the top part of s5A
mutated to cysteine, respectively, were prepared. If these resi-
dues become solvent-exposed or buried due to conformation
change, they should have different accessibility toward modifi-
cation. The variants weremixed withmPEG, a specific cysteine
alkylation reagent. Each modification will result in a 2000-Da
increase in molecular mass. The reaction was followed by SDS-
PAGE analysis. Both mutants with P14 cysteine can be readily
modified bymPEG (Fig. 4a) at a similar rate, indicating that the
P14 residue is similarly surface-exposed in both wild type
1-AT and E342A variant. The residues (336, 338, and 340)
with side chains pointing toward the hydrophobic core of the
protein on the wild type 1-AT backbone (Fig. 4b, left) are
resistant to modification as expected. Remarkably, residues on
top of s5A on E342A backbone are accessible for mPEG modi-
fication (Fig. 4b, lower gel). This further confirms that the top
half of s5A becomes labile onceGlu-342 ismutated as indicated
by the disulfide linkage experiment shown above. Also, the cys-
teine modification experiment (Fig. 4) together with fluores-
cence measurements (Fig. 3c) excludes the possibility that the
reactive center loop of Z 1-AT would stay partially inserted
(23).
Crystal Structure of Z 1-AT—To further understand the
conformation of Z 1-AT, we carried out crystallization
screens on various 1-AT mutants expressed in E. coli and on
glycosylated Z 1-AT expressed inDrosophila cells. Only crys-
tals from glycosylated recombinant Z 1-AT yielded a good
diffraction data set at 3.3 Å, and the structure was solved by
molecular replacement (Table 2). Unexpectedly, the overall
structure of Z 1-AT largely resembles that of wild type with a
closed 5-stranded -sheet A and a fully exposed reactive center
loop (Fig. 5). Although the overall resolution of the structure is
modest, the electron density map around Lys-342 is unambig-
uous as shown in Fig. 5b. It appears that the positively charged
side chain has a minimal effect on overall packing around the
hinge region of Z 1-AT. Nevertheless, superposition of wild
type 1-AT with that of Z 1-AT reveals subtle differences
between Z andwild type1-AT, with a change in orientation of
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FIGURE 4. Probing the aberrant conformation throughmPEGmodification. a, accessibilities of cysteine residue at P14 position. 1-AT (T345C) and 1-AT
(E342A/T345C) were mixed with mPEG, a specific cysteine alkylation reagent for various time intervals, and then the reaction was followed by SDS-PAGE
analysis. Each modification would result in 2000Da increase in molecular weight of  1-AT. b, accessibilities of residues of s5A in 1-AT. 1-AT variants based
on thewild typeor E342Abackboneswith residues Ile-340, Leu-338, Ala-336, andThr-345mutated to cysteine, respectively,were reactedwithmPEG.AT-mPEG
indicates the modified 1-AT. The positions of the selected residues in 1-AT structure are shown on the left. The models on the left were based on 1-anti-
chymotrypsin  form (43) in a and  1-AT in b.
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the reactive loop and a slight shift of s5A at the top half of
-sheet A (Fig. 5c). The reactive loop of Z 1-AT is fully
extended, and in the wild type 1-AT structure andmost other
inhibitory serpins the reactive center loop characteristically
takes a U turn around P17 and P16 with residues P15 and P14
poised to enter the central -sheet (Fig. 1). Close inspection of
crystal packing reveals that the P13 and P12 residues of the
reactive loop from one Z 1-AT molecule are packed against
either hH or hE from a symmetry-related molecule. It is likely
that both the crystal packing and the increased flexibility
around s5A allowZ1-AT to crystallize in a native-like confor-
mation with a relatively extended reactive loop.
Our findings here suggest that the aberrant conformation of
Z 1-AT results from a labile s5A and that stabilization of s5A
would lead to a wild type like conformation. As Z 1-AT is
largely active, it must have the ability to adopt a normal inhib-
itory conformation for protease inhibition as seen in its crystal
structure shown here. This structure of Z 1-AT allows us to
propose that Z1-AT has a labile s5A and equilibrates between
a native inhibitory conformation as shown in its crystal struc-
ture and an aberrant conformation with s5A only partially
incorporated into the central -sheet (Fig. 5d). This is consis-
tent with previous predications that Z 1-AT has an increased
flexibility around the hinge region (21, 31, 36, 38).
Binding of PBA on 1-AT—It has been shown previously that
smallmolecules, chemical chaperones such as PBA, could stim-
ulate Z1-AT secretion from cells.More importantly, PBAwas
shown to increase the concentration of Z 1-AT in circulation
in a PiZZ mouse model (39). PBA is a Food and Drug Admin-
istration-approved drug for treatment of urea cycle disorder in
humans; however, it is not well understood how this compound
functions on the Z 1-AT folding pathway. Here, we tested
whether PBA could directly bind to Z 1-AT. Fluorescence
titration measurements showed that PBA did bind to plasma Z
1-AT, but veryweaklywith a dissociation constant (Kd) of 1.23
mM. We further assessed the binding affinity of plasma M
1-AT and recombinant wild type 1-AT. They had a similar
binding affinity to PBAwith aKd of 0.011 and 0.010mM respec-
tively. In contrast, recombinant E342A mutant bound to PBA
very weakly with a Kd of 1.4 mM, similar to that of Z 1-AT
(Table 3 and Fig. 6a). To validate the Kd values measured by
fluorescence titration, we also applied the surface plasmon res-
onance experiments. The sensorgrams showed that PBA rap-
idly associated and dissociated from the immobilized 1-AT
(Fig. 6b); therefore, the Kd values could only be estimated from
a steady-state affinity model due to the fast kon and koff values
(40). Wild type 1-AT and K191A mutant bound PBA with Kd
values of 0.005 and 0.02 mM, respectively, consistent with the
values measured by fluorescence titration. The Kd value for
E342A mutant binding of PBA measured by surface plasmon
resonance was 0.1 mM, which was much smaller than the value
measured by fluorescence titration (Table 3). Thismight be due
to changes in 1-AT flexibility once protein was immobilized
onto a surface. Therefore, these measurements confirmed that
E342A and Z 1-AT mutants bound PBA significantly weaker
than wild type 1-AT.
To assess whether this increase inKd values of thesemutants
is associated with the increased flexibility of s5A, we measured
the binding affinity of 1-AT-SS-E342A mutant with s5A and
s6A linked by a disulfide bridge as described above. When the
disulfide was formed, themutant bound PBAwith aKd of 0.016
mM similar to that of wild type 1-AT (Table 3). This suggests
that the side chain of Glu-342 is not directly involved in binding
PBA, and the high binding affinity of 1-AT critically depends
on the stability of s5A. Therefore, we reasoned that the PBA-
binding site on 1-AT is likely located near the top part of s5A.
Several residues such as Lys-191, Lys-290, Thr-339, and Asp-
341 around the top part of s5A (Fig. 6c) were selected and
mutated to Ala with corresponding variants assessed for PBA
binding.We found that K191A andT339Amutants had amod-
est decrease in binding affinity with a Kd of 0.019 and 0.015 mM
toward PBA, respectively. K290Amutant bound PBAwith aKd
of 1.61 mM, similar to that of Z 1-AT (Table 3). Because Lys-
290 is involved in forming a highly conserved stabilizing inter-
action with Glu-342 (Fig. 1a), this decreased binding affinity
arose either from the labile s5A following the loss of its stabi-
lizing interactions or from the loss of the direct interaction
between Lys-290 and PBA. So we introduced K290A into
1-AT-SS-E342A backbone and measured this mutant’s bind-
ing affinity. The oxidized form of this mutant (1-AT-SS-
E342A-K290A) behaved the same as 1-AT-SS-E342A with a
Kd of 0.017 mM. Therefore, this further confirms that the stabi-
lization interactions between Glu-342 and Lys-290 and the sta-
bility of s5A are critical for high affinity PBA binding of 1-AT,
and Lys-290 does not directly interact with PBA.
Remarkably, the D341A mutant had normal activity in pro-
tease inhibition, but it had a lower basal fluorescence signal
thanwild type1-AT (Fig. 3e), and boundPBAweaklywith aKd
value the same as that of 1-AT-E342A mutant (Table 3). By
examining the crystal structures of 1-AT in the Protein Data
Bank, we found that Asp-341 was either solvent-exposed, sim-
TABLE 2
Crystallographic data collection and refinement statistics
Parameter Value
Data collection
Space group P21
Cell dimensions
(Å) a, b, c 74.13, 53.67, 110.14
(°) , ,  90, 96.88, 90
Solvent content (%) 44
Wavelength (Å) 0.9763
Resolution (Å) 74.54–3.3; 3.48–3.3
Total reflections 55,690; 7261
Unique reflections 12,855; 1803
Multiplicity 4.3; 4.0
Mean I/S.D.(I) 7.7; 1.5
Completeness (%) 98.9; 96.1
Rmerge 0.136; 0.946
Refinement
No. of atoms modeled 5836
Protein 5806
Water 2
Heterogen 28
Average B-factor (Å2) 82.96
Reflections in working/free set 11,967/642
R-factor/R-free (%) 0.22/0.28
r.m.s.a deviation of bonds (Å)/ angles (°) 0.004/0.9
Ramachandran plot (favored/outliers, %) 95.42/0
MolProbity score 1.54, 100th percentileb (n 865,
3.34 0.25 Å)
a r.m.s. is root mean square.
b 100th percentile is the best among structures of comparable resolution; 0th
percentile is the worst.
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ilar to that in Z 1-AT structure shown here, or formed hydro-
gen bonds with the main chain oxygen atom of residue 343
maintaining a U turn of the reactive loop in the hinge region
(Fig. 6c). Therefore, the decreased basal fluorescence signal of
D341A (Fig. 3e) likely arises from the fully extended reactive
loop that affects the local environment of Trp-194 below the
-sheet A. Altogether, these data suggest that Asp-341 on the
top of s5A plays a key role inmaintaining the high affinity PBA-
binding site in 1-AT, and other residues such as Lys-191, Lys-
290, Ser-292, Thr-339, andGlu-342 play aminor role.We spec-
ulate that PBA likely binds 1-AT near the breach region in
1-AT (Fig. 6).
Effect of PBA on the Aberrant Conformation of Z 1-AT—
Because PBA could bind 1-AT near the top part of s5A, we
further checked whether its binding would have any effect on
the aberrant conformation of Z 1-AT, particularly on the sta-
bility of s5A. The accessibility of residue 340 in the 1-AT-
I340C and 1-AT-E342A-I340C was similarly assessed by
mPEG modification in the presence or absence of PBA. As
shown in Fig. 6d, modification of I340C (lanes 2 and 3) and
T345C (lanes 8 and 9)mutantswere unaffected by PBA (Fig. 6d)
consistent with Fig. 4b above. However, in the absence of PBA
the I340C/E342A mutant could be modified by mPEG, and it
became resistant to modification in the presence of PBA (Fig.
6d). Furthermore, the effect of PBA on I340C modification by
mPEG was concentration-dependent (Fig. 6e). PBA was more
effective in protecting residue 340 from modification when its
concentration was10 mM. Therefore, we conclude that PBA
binds to Z 1-AT and stabilizes s5A.
Discussion
Aberrant Conformation of Z 1-AT—It has long been pro-
posed by several groups that Z 1-AT likely exists in an abnor-
mal conformation (7, 23, 30, 41, 42). The plasma-derived Z
1-AT is largely active, but polymerogenic, with higher basal
fluorescence intensity than normal M and preferential binding
of a 6-mer peptide. Our studies here are consistent with these
previous observations and have further revealed that Z muta-
tion results in the loss ofGlu-342 interactions and consequently
a labile s5A in Z 1-AT. This aberrant conformation readily
explains why Z 1-AT preferentially binds a 6-mer peptide at
the bottom half of -sheet A. Also, a labile s5A will weaken the
packing below the-sheetAofZ1-ATwith consequent expo-
sure of Trp-194 (Fig. 3) leading to polymer formation of Z
1-AT during incubation at elevated temperature.
Labile s5A and Mechanism of Z 1-AT Polymerization—As
in vivo polymerization of 1-AT caused by Z mutation occurs
mainly in the endoplasmic reticulum, this suggests that folding
intermediates, not the native state, play the dominant role in
polymerization. The mechanism underlying the pathological Z
1-AT deficiency will be centered on the following two inter-
linked questions. How is 1-AT folded into a metastable con-
formation and how does the Z mutation disrupt the folding
pathway and lead to polymerization? Understanding the fold-
ing defects of Z 1-AT is critical for selecting and designing
reagents to rectify the Z 1-AT folding process. As we have
shown here, the Z mutation will disrupt the packing of central
-sheet A and lead to a labile s5A. We believe that the same
defect would perturb a key step in the 1-AT folding pathway
and result in the pathological polymerization of Z 1-AT.
Our findings here fit best with the sequential folding pathway
proposed byDolmer andGettins (21) andwith the crystal struc-
ture of 1-AT trimer solved by the Huntington and co-workers
(17). In this folding model (Fig. 7), the N-terminal portion of a
serpin is first folded into a molten globule-like conformation
with incomplete -sheets A and B and an unstructured C-ter-
minal portion (Fig. 7i). The next step of folding is the associa-
tion of s5A (Fig. 7iii, blue), not s4/5B. Once the native-like five-
stranded conformation of -sheet A has been completed (Fig.
7iii), the C-terminal portion, including the reactive loop (which
would become s4A in the hyperstable state) and strand s1C and
s4/5B, then starts to associate. It is through this ordered folding
process that the serpin avoids a hyperstable conformation and
folds into a metastable native state (Fig. 7iv) (21).
It is clear from this folding pathway how Z 1-AT would
form polymers (21). As illustrated above (Fig. 7), annealing of
s5A into the central -sheet is critical for the subsequent fold-
ing steps. Loss of the key interactions caused by the Zmutation
will result in an intermediate conformation (Fig. 7ii) with a
partially inserted s5A. Because s5A of Z 1-AT could tran-
siently fully incorporate into the -sheet A (Fig. 7iii), as con-
firmed by its inhibitory activity and the crystal structure here, a
small amount of Z 1-AT could be folded, with a properly
inserted s4/5B (Fig. 7iv), and hence be secreted. This explains
why there is15% of active Z 1-AT monomer present in the
circulation. However, the majority of this intermediate confor-
FIGURE5.Structuresof Z1-AT.a, crystal structure of glycosylatedZ1-AT variant (M358R, C232S, and E342K) shows that Z1-AThas a typical inhibitory fold
as seen with other native serpins with a closed central sheet A (red) and a surface-exposed reactive loop (yellow). The C-terminal portion is colored in cyan. b,
electron density map contoured at 1.0  around the hinge region shows an extended reactive loop in Z 1-AT. Residues 342, Thr-203, and Lys-290 occupy
similar positions as seen inwild type. c, stereo view of overlaid structures of wild type (Protein Data Bank code 1QLP, black) and Z1-AT (green). There are only
subtle changes around the hinge region (arrow) and the gate region (circled dashed line) in Z1-ATwhen comparedwithwild type1-antitrypsin. d, simplified
model of Z 1-AT conformations. Because of the loss of stabilizing interactions at position 342, the s5A (blue) of Z 1-AT is labile and equilibrates between
partially and fully inserted conformations. It is likely the predominant conformation of Z1-AT has a partially inserted s5A (left, aberrant conformation), which
could readily form a binding site, with s3A, for the 6-mer peptide. Carbon  of residue 342 is shown as a brown sphere.
TABLE 3
Kd values for1-AT variants bindingof PBAmeasuredby fluorescence
titration and surface plasmon resonance assays
All the variants are based on 1-AT Pittsburgh backbone with (M358R and C232S).
The oxidized form of 1-AT-SS-E342A is termed Oxi here.
Fluorescence
Kd
Surface plasmon
resonance Kd
mM mM
WT 0.010 0.003 0.005 0.001
E342A 1.4 0.2 0.100 0.025
K191A 0.019 0.006 0.020 0.003
T339A 0.015 0.002
K290A 1.61 0.30
D341A 1.38 0.20
Oxi 0.016 0.005
Oxi -K290A 0.017 0.007
M 1-AT 0.011 0.004
Z 1-AT 1.23 0.14
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mation would accumulate due to the delayed folding process
caused by the Z mutation and will be prone to intermolecular
insertion of s4/5B (Fig. 7vi). This will lead to polymer formation
consistent with the crystal structure of an 1-AT trimer (Fig.
1e) where polymers are formed though a C-terminal s4/5B
domain swap mechanism (17). Similarly, other mutations
around the shutter region of 1-AT affecting either the anneal-
ing of s5A or subsequent insertion of C-terminal s1C and s4/5B
would slow down the formation of the nativemonomer, predis-
posing to intermolecular linkage and subsequent polymer for-
mation (Fig. 7).
When Z 1-AT derived from plasma, folded but with a labile
conformation (Fig. 7v), is heated in vitro, its C-terminal portion,
including the reactive center loop (yellow) and strands 1C,
s4/5B (cyan or green), will predictably be readily detached from
the main body of the molecule due to weakened packing
FIGURE 6. Binding of PBA on 1-AT. a, binding affinities of 1-AT E342A mutant and WT 1-AT were measured by fluorescent titration with estimated Kd
values of 1.4 0.2mM for E342Amutant (n 3) and 0.010 0.003mM forWT (n 3), respectively. b,BIAcore diagramof PBAbinding toWT1-AT showed that
PBA rapidly associated and dissociated from the immobilized 1-AT. Kd value was estimated from a steady-state affinity model by BIAcore T200 analysis
software. c, residues around the hinge region were mutated in 1-AT and assessed for PBA binding. The corresponding Kd values are listed in Table 3. The
breach region for the reactive loop to insert is circled by dashed lines. d, PBA effect on the accessibility of cysteine residues in 1-AT variants was assessed by
mPEGmodification where 1-AT variants (I340C, E342A/I340C, and T345C) were mixed with 20 M mPEG in the presence or absence of 100 mM PBA at room
temperature for 10 min before being analyzed by SDS-PAGE. e, concentration effect of PBA on modification of E342A/I340C mutant by mPEG was similarly
assessed in the presence of different concentrations of PBA. AT-mPEG, mPEGmodified  1-AT.
Molecular Mechanism of Z1-Antitrypsin Deficiency
15682 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 291•NUMBER 30•JULY 22, 2016
between -sheet A and B. This intermediate conformation
likely resembles those of the serpin folding pathway (Fig. 7, ii
and iii) and is prone to intermolecular linkage. Once the reac-
tive loop of the interlinked molecule (Fig. 7vi) inserts as a mid-
dle strand of the central -sheet A, this process will be irrevers-
ible leading to hyperstable polymer formation (Fig. 1e).
Therapeutic Approach toward Z1-ATDeficiency by Target-
ing Labile s5A—There have been numerous attempts to design
and select reagents to prevent Z 1-AT polymerization (13, 39,
43, 44). So far, the most effective compound is PBA discovered
by serendipity, which can increase Z 1-AT in PiZZ in mouse
circulation (39). Although the chemical chaperones are often
considered to function through nonspecific binding, some do
directly interact with ligands or the protein active site (45, 46).
Here, we have found that PBA could readily bind wild type
1-AT relatively tightly with a Kd of 10 M, but it binds Z
1-AT more than 120 times weaker (Fig. 6). Our mutagenesis
study indicates that the binding site is located near the hinge
region with residue Asp-341 playing a key role in maintaining
the high binding affinity. More importantly, we show that PBA
binding could stabilize the top half of s5A (Fig. 6). Although the
physiological role of the specific interactions between PBA and
Z 1-AT requires further investigation, we speculate that PBA
could act similarly in stabilizing s5Aduring the folding pathway
(Fig. 7iii) in vivo promoting the folding of monomeric Z 1-AT
and subsequent secretion from the cells. Therefore, targeting
labile s5A could be a viable approach toward Z 1-AT defi-
ciency. The limited effect of PBA in human Z 1-AT patients
(47) may arise from the poor binding affinity of PBA toward Z
1-AT and its severe side effects.
Overall, our data show here the Z mutation destabilizes the
s5A of 1-AT leading to an aberrant conformation of Z 1-AT
viii iiiv
U
ivi
?
??????????
???????????
???????????
???????????
???????????
P
FIGURE 7. Role of s5A in the folding and polymerization pathway of 1-AT. When the nascent 1-AT polypeptide chain is synthesized, its N-terminal
portion is first folded into amoltenglobule-like conformationwith incomplete-sheets A (red) andB and theunstructuredC-terminal portion (i). Normally, the
next stepof folding is the associationof s5A (iii), not s4/5B (21). Once thenative-like 5-strand conformationof-sheet A (iii) has been completed, theC-terminal
portion, including the reactive center loop (yellow) and strands 1C, s4/5B (cyan or green) then starts to associate and form, thus forming the metastable
conformation (iv). Because of mutation at 342 (brown sphere), the s5A (blue) of Z 1-AT could not stably anneal into the central -sheet A leading to
accumulation of an intermediate conformation with a partially inserted s5A (ii). Subsequent inter-molecular insertion of the C-terminal portion (vi) and
rearrangement of the reactive loop lead to hyper-stable serpin polymer (P) formation. When folded Z 1-AT (v) is incubated at elevated temperature, the
C-terminal portion becomes unstable and is released due to weakened packing between -sheet A and B (ii). Subsequently, the same inter-molecular linkage
could occur. Once the reactive loop (yellow) from the interlinkedmolecules (vi) starts to insert into the central-sheet A as in Fig. 1b, thewhole process become
irreversible leading to serpin polymer formation. Small compounds such as PBA (yellow star) may bind and stabilize s5A in the intermediate conformation (iii)
during the folding pathway promoting nativemetastable conformation formation (iv). Although s6A is likely disordered in the absence of s5A (39), it is shown
here as a -strand for simplicity.
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monomer. The same defect would disrupt a key step in 1-AT
folding pathway leading to the pathological Z 1-AT polymer-
ization via the C-terminal s4/5B domain swap mechanism (17,
21). Most importantly, our finding demonstrates that previ-
ously identified small molecule PBA, which partially amelio-
rates Z 1-AT deficiency in mice, may act on Z 1-AT by sta-
bilizing s5A. This opens a potential therapeutic approach
toward Z 1-AT deficiency by designing and selecting more
effective agents through targeting the top half of s5A.
Experimental Procedures
Preparation and Characterization of 1-Antitrypsin
Variants—Human 1-AT cDNA was amplified by polymerase
chain reaction and inserted into the expression vector pQE31 as
described previously (48). All the1-AT variants were based on
the 1-AT Pittsburgh backbone (M358R and C232S) and veri-
fied by DNA sequencing. The recombinant 1-AT was
expressed with an MRSHHHHHH tag at the N terminus and
purified from the soluble fraction of E. coli lysate. All the
recombinant proteins were purified to homogeneity (95%
purity) and confirmed by SDS-PAGE. Modification of the
E342C 1-ATmutant by aminoethyl-8 reagent (N-(iodoethyl)-
trifluoroacetamide, Pierce) was performed at pH 8.5 according
to the manufacturer’s instructions. The modified variant is
termed E342C-mod and was verified by mass spectrometry. It
migrates slower than the E342C variant in a native gel.
Recombinant glycosylated 1-AT was also prepared from
Drosophila S2 cells using expression vector pMT/BiP/V5-His.
Expression of the recombinant Z 1-AT (M358R, C232S,
T345C, and E342K), where P1 residueMet-358 was mutated to
Arg for convenient activity assessment and P14 residue Thr-
345 was mutated to Cys for probing the conformation of the
reactive loop around the hinge region, was induced by adding
0.5mM copper sulfate into S2 cell culture at 23 °C. The secreted
recombinant protein was purified from themedium using nickel-
chelating Sepharose beads and subsequent HiTrap Q ion
exchange chromatography. The behavior of the recombinant Z
variant is similar to that of plasma-derived Z 1-AT in prefer-
ential binding of the 6-mer peptide (FLEAIG) (23). Plasma-
derived Z1-ATwas provided byDr. Helen Parfrey, University
of Cambridge (35). Peptide insertion experiments were per-
formed by incubating 1-AT variants (0.5 mg/ml) with 100-
fold molar excess of peptides for different time intervals at
37 °C. Samples were then analyzed on an 8% (w/v) native gel with
7Murea. Stoichiometries and ratesof inhibition for the interaction
between 1-AT and proteases were performed as described pre-
viously (48). Binding affinity of PBA toward 1-AT variants was
measured by titrating PBA stock solution into 1-AT with the
decreased fluorescence signal of 1-AT followed (49). Modifica-
tion of free thiol group in cysteine byNEM-PEG2000 (mPEG)was
performed as described previously (50).
Refolding of 1-AT—Small scale protein refolding assays
were performed by placing a small droplet of denatured 1-AT
Pittsburgh (termed wild type) or E342H mutant in 6 M guani-
dine HCl at the bottom of a microcentrifuge tube and quickly
diluting the proteinwith buffers at different pH values (pH5–9)
containing 100mMNaCl. For the activity assay, refolded1-AT
was directly mixed with excess thrombin and incubated at
room temperature for 15min and then analyzed by SDS-PAGE
and/or Western blotting.
Binding Affinity Measurement—The affinity of PBA toward
1-AT variants was measured by the fluorescence titration
method where stock solutions of PBA were gradually titrated
into 1-AT in phosphate-buffered saline with the fluorescence
signal of the protein recorded at the 340-nm wavelength. The
dissociation constant of the binding (Kd) was fitted with 1:1
binding mode by Origin software. The affinity of PBA toward
1-AT variants was also analyzed on a BIAcore T200 machine
withCM7chips (GEHealthcare). PBSPbuffer (phosphate-buff-
ered saline containing 0.005% P20) was used as the analysis
buffer. 1-AT variants were immobilized on the chip through
amine coupling chemistry, and PBA was diluted to concentra-
tions ranging from 6.25 to 210M. PBAwas flowed through the
chip at a rate of 30l/min, and the response unit wasmeasured.
The sensor surfacewas regeneratedwith 10mMglycine, pH 2.5,
at the end of each cycle. Sensorgrams were fitted with BIAcore
T200 analysis software using a 1:1 binding mode, and the Kd
values were calculated with a steady-state affinity model due to
the fast kon and koff (40).
Crystallization of Z 1-AT and Data Collection and
Refinement—Recombinant Z 1-AT (M358R, C232S, T345C,
and E342K) derived from S2 cells was concentrated to 17.2
mg/ml in 10 mM Tris-HCl, 50 mM NaCl. Crystallization was
performed using sitting drop methods where Z 1-AT was
mixed with equal volumes of reservoir solution and equili-
brated against 10–20% PEG 4000 in 50 mM sodium cacodylate
buffer, pH 6.8, and 0.2 M NH4F, with or without 12% glycerol.
Thin plate-like crystals grew to full size in 2 weeks. Diffraction
data up to 3.3 Å were collected from a single frozen crystal and
processed withMosflm and Scala from the CCP4 suite (51, 52).
The structure was solved by Phaser (53) using Protein Data
Bank code 1QLP (13) as a search model, and refinement was
performed with Refmac from the CCP4 suite. Processing and
refinement statistics are summarized in Table 2. The final
refined structure has two copies in the asymmetric unit. Resi-
dues 1–23 and 347–352 in molecule A and residues 1–23 and
348–354 in molecule B are unresolved. The coordinates and
structure factors have been deposited in the Protein Data Bank
(accession number 5IO1). Carbohydrates at glycosylation sites
ASN46 were not built into the model due to relatively weak
electron density. Figures were made using PyMOL (54).
Author Contributions—A. Z. and G. C. designed all experiments.
X. H., Y. Z., F. Z., Z. W., R. J. R., and A. Z. performed the experi-
ments. All authors contributed to data analysis. X. H., Y. Z., R. W. C.,
R. J. R., and G. C. contributed to manuscript preparation, and A. Z.
wrote the paper.
Acknowledgments—We thank the staff at SSRF beamline BL17U and
19U for assistance and Dr. Zhiyong Xu for help with surface plasmon
resonance experiments.
References
1. Huber, R., and Carrell, R.W. (1989) Implications of the three-dimensional
structure of1-antitrypsin for structure and function of serpins.Biochem-
istry 28, 8951–8966
Molecular Mechanism of Z1-Antitrypsin Deficiency
15684 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 291•NUMBER 30•JULY 22, 2016
2. Irving, J. A., Pike, R. N., Lesk, A.M., andWhisstock, J. C. (2000) Phylogeny
of the serpin superfamily: implications of patterns of amino acid conser-
vation for structure and function. Genome Res. 10, 1845–1864
3. Gettins, P. G. (2002) Serpin structure, mechanism, and function. Chem.
Rev. 102, 4751–4804
4. Huntington, J. A., Read, R. J., and Carrell, R. W. (2000) Structure of a
serpin-protease complex shows inhibition by deformation. Nature 407,
923–926
5. Stratikos, E., and Gettins, P. G. (1999) Formation of the covalent serpin-
proteinase complex involves translocation of the proteinase by more than
70 A and full insertion of the reactive center loop into -sheet A. Proc.
Natl. Acad. Sci. U.S.A. 96, 4808–4813
6. Loebermann, H., Tokuoka, R., Deisenhofer, J., and Huber, R. (1984) Hu-
man 1-proteinase inhibitor. Crystal structure analysis of two crystal
modifications, molecular model and preliminary analysis of the implica-
tions for function. J. Mol. Biol. 177, 531–557
7. Carrell, R. W., and Lomas, D. A. (2002) 1-Antitrypsin deficiency–a
model for conformational diseases. N. Engl. J. Med. 346, 45–53
8. Davies, M. J., and Lomas, D. A. (2008) The molecular aetiology of the
serpinopathies. Int. J. Biochem. Cell Biol. 40, 1273–1286
9. Laurell, C.-B., and Eriksson, S. (1963) The electrophoretic 1-globulin
pattern of serum in 1-antitrypsin deficiency. Scand. J. Clin. Lab. Invest.
15, 132–140
10. Sharp, H. L., Bridges, R. A., Krivit, W., and Freier, E. F. (1969) Cirrhosis
associated with -1-antitrypsin deficiency: a previously unrecognized in-
herited disorder. J. Lab. Clin. Med. 73, 934–939
11. Cox, D. W., Billingsley, G. D., and Callahan, J. W. (1986) Aggregation of
plasmaZ type1-antitrypsin suggests basic defect for the deficiency. FEBS
Lett. 205, 255–260
12. Lomas, D. A., Evans, D. L., Finch, J. T., and Carrell, R. W. (1992) The
mechanism of Z 1-antitrypsin accumulation in the liver. Nature 357,
605–607
13. Elliott, P. R., Pei, X. Y., Dafforn, T. R., and Lomas, D. A. (2000) Topography
of a 2.0 A structure of 1-antitrypsin reveals targets for rational drug
design to prevent conformational disease. Protein Sci. 9, 1274–1281
14. Ekeowa, U. I., Freeke, J., Miranda, E., Gooptu, B., Bush, M. F., Pérez, J.,
Teckman, J., Robinson, C. V., and Lomas, D. A. (2010) Defining themech-
anismof polymerization in the serpinopathies.Proc.Natl. Acad. Sci. U.S.A.
107, 17146–17151
15. Mast, A. E., Enghild, J. J., and Salvesen, G. (1992) Conformation of the
reactive site loop of 1-proteinase inhibitor probed by limited proteolysis.
Biochemistry 31, 2720–2728
16. Yamasaki, M., Li, W., Johnson, D. J., and Huntington, J. A. (2008) Crystal
structure of a stable dimer reveals the molecular basis of serpin polymer-
ization. Nature 455, 1255–1258
17. Yamasaki, M., Sendall, T. J., Pearce, M. C., Whisstock, J. C., and Hunting-
ton, J. A. (2011) Molecular basis of 1-antitrypsin deficiency revealed by
the structure of a domain-swapped trimer. EMBO Rep. 12, 1011–1017
18. Krishnan, B., and Gierasch, L. M. (2011) Dynamic local unfolding in the
serpin -1 antitrypsin provides a mechanism for loop insertion and poly-
merization. Nat. Struct. Mol. Biol. 18, 222–226
19. Miranda, E., Pérez, J., Ekeowa, U. I., Hadzic, N., Kalsheker, N., Gooptu, B.,
Portmann, B., Belorgey,D.,Hill,M., Chambers, S., Teckman, J., Alexander,
G. J., Marciniak, S. J., and Lomas, D. A. (2010) A novel monoclonal anti-
body to characterize pathogenic polymers in liver disease associated with
1-antitrypsin deficiency. Hepatology 52, 1078–1088
20. Ekeowa, U. I., Gooptu, B., Belorgey, D., Hägglöf, P., Karlsson-Li, S., Mi-
randa, E., Pérez, J., MacLeod, I., Kroger, H., Marciniak, S. J., Crowther,
D. C., and Lomas, D. A. (2009) 1-Antitrypsin deficiency, chronic ob-
structive pulmonary disease and the serpinopathies. Clin. Sci. 116,
837–850
21. Dolmer, K., andGettins, P. G. (2012) How the serpin 1-proteinase inhib-
itor folds. J. Biol. Chem. 287, 12425–12432
22. Tsutsui, Y., Dela Cruz, R., andWintrode, P. L. (2012) Folding mechanism
of the metastable serpin 1-antitrypsin. Proc. Natl. Acad. Sci. U.S.A. 109,
4467–4472
23. Mahadeva, R., Dafforn, T. R., Carrell, R.W., andLomas,D.A. (2002) 6-mer
peptide selectively anneals to a pathogenic serpin conformation and
blocks polymerization. Implications for the prevention of Z(1)-antitryp-
sin-related cirrhosis. J. Biol. Chem. 277, 6771–6774
24. Foreman, R. C. (1987) Disruption of the Lys-290–Glu-342 salt bridge in
human 1-antitrypsin does not prevent its synthesis and secretion. FEBS
Lett. 216, 79–82
25. Brantly,M., Courtney,M., andCrystal, R. G. (1988) Repair of the secretion
defect in the Z form of 1-antitrypsin by addition of a second mutation.
Science 242, 1700–1702
26. Sifers, R. N., Hardick, C. P., and Woo, S. L. (1989) Disruption of the
290–342 salt bridge is not responsible for the secretory defect of the PiZ
1-antitrypsin variant. J. Biol. Chem. 264, 2997–3001
27. Wu, Y., and Foreman, R. C. (1990) The effect of amino acid substitutions
at position 342 on the secretion of human 1-antitrypsin from Xenopus
oocytes. FEBS Lett. 268, 21–23
28. Owen, M. C., Brennan, S. O., Lewis, J. H., and Carrell, R. W. (1983) Mu-
tation of antitrypsin to antithrombin. 1-Antitrypsin Pittsburgh (358Met
leads to Arg), a fatal bleeding disorder. N. Engl. J. Med. 309, 694–698
29. Zhou, A., and Carrell, R. W. (2008) Dimers initiate and propagate serine
protease inhibitor polymerisation. J. Mol. Biol. 375, 36–42
30. Lomas, D. A., Evans, D. L., Stone, S. R., Chang, W.-S., and Carrell, R. W.
(1993) Effect of theZmutation on the physical and inhibitory properties of
1-antitrypsin. Biochemistry 32, 500–508
31. Levina, V., Dai, W., Knaupp, A. S., Kaiserman, D., Pearce, M. C.,
Cabrita, L. D., Bird, P. I., and Bottomley, S. P. (2009) Expression, puri-
fication and characterization of recombinant Z (1)-antitrypsin–the
most common cause of (1)-antitrypsin deficiency. Protein Expr. Purif.
68, 226–232
32. Ogushi, F., Fells, G. A., Hubbard, R. C., Straus, S. D., and Crystal, R. G.
(1987) Z-type1-antitrypsin is less competent thanM1-type1-antitryp-
sin as an inhibitor of neutrophil elastase. J. Clin. Invest. 80, 1366–1374
33. Schulze, A. J., Baumann,U., Knof, S., Jaeger, E., Huber, R., andLaurell, C. B.
(1990) Structural transition of 1-antitrypsin by a peptide sequentially
similar to -strand s4A. Eur. J. Biochem. 194, 51–56
34. Skinner, R., Chang,W. S., Jin, L., Pei, X., Huntington, J. A., Abrahams, J. P.,
Carrell, R. W., and Lomas, D. A. (1998) Implications for function and
therapy of a 2.9 A structure of binary-complexed antithrombin. J. Mol.
Biol. 283, 9–14
35. Zhou, A., Stein, P. E., Huntington, J. A., Sivasothy, P., Lomas, D. A., and
Carrell, R. W. (2004) How small peptides block and reverse serpin po-
lymerisation. J. Mol. Biol. 342, 931–941
36. Kass, I., Knaupp, A. S., Bottomley, S. P., and Buckle, A. M. (2012) Confor-
mational properties of the disease-causing Z variant of 1-antitrypsin
revealed by theory and experiment. Biophys. J. 102, 2856–2865
37. Gooptu, B., Hazes, B., Chang, W. S., Dafforn, T. R., Carrell, R. W., Read,
R. J., and Lomas, D. A. (2000) Inactive conformation of the serpin (1)-
antichymotrypsin indicates two-stage insertion of the reactive loop: im-
plications for inhibitory function and conformational disease. Proc. Natl.
Acad. Sci. U.S.A. 97, 67–72
38. Hughes, V. A., Meklemburg, R., Bottomley, S. P., and Wintrode, P. L.
(2014) The Z mutation alters the global structural dynamics of 1-antit-
rypsin. PLoS One 9, e102617
39. Burrows, J. A., Willis, L. K., and Perlmutter, D. H. (2000) Chemical chap-
erones mediate increased secretion of mutant 1-antitrypsin (1-AT) Z:
A potential pharmacological strategy for prevention of liver injury and
emphysema in 1-AT deficiency. Proc. Natl. Acad. Sci. U.S.A. 97,
1796–1801
40. Zhang,W., Shi, Y., Lu, X., Shu, Y., Qi, J., and Gao, G. F. (2013) An airborne
transmissible avian influenza H5 hemagglutinin seen at the atomic level.
Science 340, 1463–1467
41. James, E. L., Whisstock, J. C., Gore, M. G., and Bottomley, S. P. (1999)
Probing the unfolding pathway of 1-antitrypsin. J. Biol. Chem. 274,
9482–9488
42. Yu, M. H., Lee, K. N., and Kim, J. (1995) The Z type variation of human
1-antitrypsin causes a protein folding defect. Nat. Struct. Biol. 2,
363–367
43. Mallya, M., Phillips, R. L., Saldanha, S. A., Gooptu, B., Brown, S. C.,
Termine, D. J., Shirvani, A. M., Wu, Y., Sifers, R. N., Abagyan, R., and
Lomas, D. A. (2007) Small molecules block the polymerization of Z
Molecular Mechanism of Z1-Antitrypsin Deficiency
JULY 22, 2016•VOLUME 291•NUMBER 30 JOURNAL OF BIOLOGICAL CHEMISTRY 15685
1-antitrypsin and increase the clearance of intracellular aggregates.
J. Med. Chem. 50, 5357–5363
44. Ordóñez, A., Pérez, J., Tan, L., Dickens, J. A., Motamedi-Shad, N., Irving,
J. A., Haq, I., Ekeowa, U., Marciniak, S. J., Miranda, E., and Lomas, D. A.
(2015) A single-chain variable fragment intrabody prevents intracellular
polymerization of Z 1-antitrypsin while allowing its antiproteinase ac-
tivity. FASEB J. 29, 2667–2678
45. Yancey, P. H., Clark, M. E., Hand, S. C., Bowlus, R. D., and Somero, G. N.
(1982) Living with water stress: evolution of osmolyte systems. Science
217, 1214–1222
46. Arakawa, T., Ejima, D., Kita, Y., and Tsumoto, K. (2006) Small molecule
pharmacological chaperones: From thermodynamic stabilization to phar-
maceutical drugs. Biochim. Biophys. Acta 1764, 1677–1687
47. Teckman, J. H. (2004) Lack of effect of oral 4-phenylbutyrate on serum
-1-antitrypsin in patients with -1-antitrypsin deficiency: a preliminary
study. J. Pediatr. Gastroenterol. Nutr. 39, 34–37
48. Zhou, A., Stein, P. E., Huntington, J. A., and Carrell, R. W. (2003) Serpin
polymerization is prevented by a hydrogen bond network that is centered
on His-334 and stabilized by glycerol. J. Biol. Chem. 278, 15116–15122
49. Olson, S. T., and Shore, J. D. (1981) Binding of high affinity heparin to
antithrombin III. Characterization of the protein fluorescence enhance-
ment. J. Biol. Chem. 256, 11065–11072
50. Zhou, A., Carrell, R. W., Murphy, M. P., Wei, Z., Yan, Y., Stanley, P. L.,
Stein, P. E., Broughton Pipkin, F., and Read, R. J. (2010) A redox switch in
angiotensinogen modulates angiotensin release. Nature 468, 108–111
51. Murshudov, G. N., Vagin, A. A., and Dodson, E. J. (1997) Refinement of
macromolecular structures by the maximum-likelihood method. Acta
Crystallogr. D Biol. Crystallogr. 53, 240–255
52. Battye, T. G., Kontogiannis, L., Johnson, O., Powell, H. R., and Leslie, A. G.
(2011) iMOSFLM: a new graphical interface for diffraction-image pro-
cessing withMOSFLM.Acta Crystallogr. D Biol. Crystallogr. 67, 271–281
53. McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Sto-
roni, L. C., and Read, R. J. (2007) Phaser crystallographic software. J. Appl.
Crystallogr. 40, 658–674
54. Delano, W. (2003) The PyMOL Molecular Graphics System, Educational
Version. DeLano Scientific LLC, San Diego
Molecular Mechanism of Z1-Antitrypsin Deficiency
15686 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 291•NUMBER 30•JULY 22, 2016
